Home » Topics » BioWorld Science

BioWorld Science
RSS

Cassiopea reports phase III topline results for topical antiandrogen Winlevi for acne

July 10, 2018

Pfizer divulges glucagon-like peptide 1 receptor agonists

July 10, 2018

KCNC1/KCNC2 channel modulators presented by Autifony Therapeutics

July 10, 2018

Amgen discovers new beta-secretase inhibitors

July 10, 2018

CPL-207-280CA demonstrates improved glycemic control and safety in vivo

July 10, 2018

Matinas collaborates with NINDS to develop HIV therapy based on LNC platform

July 10, 2018

Bellus Health initiates phase I study of BLU-5937 for the treatment of chronic cough

July 10, 2018

Catabasis announces plans for phase III trial of edasalonexent in DMD

July 10, 2018

MediciNova announces subgroup analyses from trial of MN-166 in ALS

July 10, 2018

Intrapulmonary penetration of ETX-2514SUL supports development for respiratory infections

July 10, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...